Mesa Labs Announces First Quarter Results

LAKEWOOD, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q27”) ended June 30, 2026 (amounts in thousands).

1Q27 Financial Summary – (comparisons are versus the same prior year period) * Revenues increased 1.0% * Non-GAAP organic and core organic revenues(1) growth was 1.0% and 0.4%, respectively * Operating income increased 129% to $7,031 * Non-GAAP adjusted operating income (“AOI”) excluding unusual items(2) increased 19.5% and was 25.6% as a percentage of revenues * Repaid $8,656 of debt and reduced Total Net Leverage Ratio(3) to 1.85 We operate our business in four divisions: Sterilization and Disinfection Control (“SDC”), Biopharmaceutical Development (“BPD”), Calibration Solutions (“CS”), and Clinical Genomics (“CG”).